




The relative strengths and weaknesses of Provectus Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provectus Biopharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 0.028% points. The greatest weakness of Provectus Biopharmaceuticals INC is the variable Assets, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.043%, being 234% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	7,706
Cost of Goods Sold	15
Intangible Assets	5,597
Liabilities, Current	263
Liabilities, Non-Current	0
Other Assets	27
Other Compr. Net Income	0
Other Expenses	14,216
Other Liabilities	3,067
Other Net Income	4,025
Other Revenues	40
Property and Equipment	20
Research and Development	38,093
Selling, General and Administrative Expense	57,525

Output Variable	Value in 1000 USD
Assets	13,350
Liabilities	3,330
Expenses	109,850
Revenues	40
Stockholders Equity	10,020
Net Income	-105,785
Comprehensive Net Income	-105,785
BaseVar	65,298
ECR before LimitedLiability	-1,006%
Economic Capital Ratio	0.043%